Research Article, J Virol Antivir Res Vol: 3 Issue: 2
Treatment Response and Tolerability in Elderly Patients with Chronic Hepatitis C: Subgroup Analysis in ReGIT-J Study
| Hiroki Nishikawa1, Hirayuki Enomoto2, Masaki Saito2, Nobuhiro Aizawa2, Yasuhiro Tsuda3, Kazuhide Higuchi3, Kazuichi Okazaki4, Toshihito Seki4, Soo Ryang Kim5, Yasushi Hongo6, Hisato Jyomura7, Naoshi Nishida8, Masatoshi Kudo8, Yukio Osaki1 and Shuhei Nishiguchi2 | |
| 1Department Gastroenterology and Hepatology, Osaka Red Cross Hospital, Osaka, Japan | |
| 2Division of Hepatobiliary and Pancreatic disease, Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan | |
| 3Second Department of Internal Medicine, Osaka Medical College, Osaka, Japan | |
| 4Department of Gastroenterology and Hepatology, Kansai Medical University, Osaka, Japan | |
| 5Department of Internal Medicine, Kobe Asahi Hospital, Hyogo, Japan | |
| 6Department of Gastroenterology and Hepatology, Hirakata City Hospital, Osaka, Japan | |
| 7Wakakoukai Medical Clinic, Osaka, Japan | |
| 8Department of Gastroenterology and Hepatology, Kinki University School of Medicine, Osaka, Japan | |
| Corresponding author : Hiroki Nishikawa MD, Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital, 5-30 Fudegasaki-cho, Tennoji-ku, Osaka 543-0027, Japan Tel: +81-6-6774-5111; Fax: +81-6-6774-5131 E-mail: h-nishikawa@osaka-med.jrc.or.jp |
|
| Received: May 23, 2014 Accepted: June 24, 2014 Published: June 26, 2014 | |
| Citation: Nishikawa H, Hirayuki E, Saito M, Aizawa N, Tsuda Y, et al.(2014) Treatment Response and Tolerability in Elderly Patients with Chronic Hepatitis C: Subgroup Analysis in ReGIT-J Study. J Virol Antivir Res 3:2. doi:10.4172/2324-8955.1000125 |
Abstract
Treatment Response and Tolerability in Elderly Patients with Chronic Hepatitis C: Subgroup Analysis in ReGIT-J Study
Background: We previously reported response-guided therapy (RGT) of peginterferon (Peg-IFN)-2a with or without ribavirin (RBV) for chronic hepatitis C (CHC) of genotype 1b (a multicenter randomized trial, ReGIT-J study). Here, we performed a subgroup analysis of the ReGIT-J study according to age. Methods: The sustained virological response (SVR) rate and the treatment discontinuation rate were calculated in both groups. Results: In the elderly group (65 years, n=54), the SVR rate in the RGT group was higher than in the non- RGT group (50% [9/18] vs 36% [8/22], P=0.385). Similarly, in the control group (<65 years, n=132), the SVR rate in the RGT group was higher than in the non-RGT group (65% [31/48] vs 50% [27/54], P=0.138). In the elderly group, the discontinuation rate in the RGT group was almost significantly lower than in the non-RGT group (0% [0/18] vs 18% [4/22], P=0.057), whereas in the control group, the difference between the groups was not significant (4% [2/48] vs 13% [7/54], P=0.118). Furthermore, in all subgroup analyses, there was no significant difference between the elderly and control groups in terms of treatment response. Conclusion: Our proposed RGT was well tolerated in elderly CHC patients treated with Peg-IFN-2a with or without RBV.
